Can Cytarabine Be Given Subcutaneously?
Yes, cytarabine can be administered subcutaneously, and the standard injection sites are the abdomen, thigh, buttocks, and upper arm—the same sites used for other subcutaneous medications.
Route of Administration
Cytarabine is explicitly approved for subcutaneous administration according to FDA labeling. The FDA label clearly states that cytarabine "may be given by intravenous infusion or injection, subcutaneously, or intrathecally" 1. This is not an off-label use but rather an established route of delivery.
Appropriate Injection Sites
Based on the FDA label and clinical trial data, cytarabine can be injected at standard subcutaneous sites 1:
- Abdomen (avoiding approximately 2 fingerbreadths around the umbilicus)
- Upper third anterior lateral aspect of both thighs
- Posterior lateral aspect of both upper buttocks and flanks
- Middle third posterior aspect of the upper arm
While the cytarabine FDA label doesn't specify exact anatomical boundaries, general subcutaneous injection principles apply (similar to insulin administration guidelines). The key is to inject into healthy subcutaneous tissue while avoiding areas with lipohypertrophy, scars, or inflammation 2.
Clinical Evidence for Subcutaneous Use
Low-dose cytarabine given subcutaneously is well-established in AML treatment guidelines. Multiple NCCN guidelines from 2019 describe the standard low-intensity regimen as "low-dose cytarabine subcutaneously (20 mg twice daily for 10 consecutive days, every 4–6 weeks)" 3. This was the dosing schedule used in the UK NCRI AML 14 trial, which demonstrated clinical benefit in older patients unfit for intensive chemotherapy 3.
The subcutaneous route has been "well tolerated" according to the FDA label, with only rare instances of pain and inflammation at injection sites 1. This contrasts with intravenous administration, where thrombophlebitis can occur.
Practical Considerations
- Rotation of injection sites is essential to prevent lipohypertrophy and ensure consistent absorption
- Avoid injecting into the same site repeatedly—rotate systematically within one anatomical area rather than jumping between different body regions
- The subcutaneous route is particularly useful when intravenous access is difficult or impractical, as demonstrated in case reports of patients with Langerhans cell histiocytosis 4
- Pharmacokinetic studies in animal models show that subcutaneous cytarabine achieves predictable plasma concentrations with linear dose-exposure relationships 5, 6
Common Pitfall to Avoid
Do not assume subcutaneous cytarabine is only for palliative or low-intensity regimens. While most commonly used for low-dose protocols (20 mg twice daily), the subcutaneous route is an FDA-approved administration method that can be employed when clinically appropriate, particularly in patients where venous access is challenging or for outpatient convenience in low-intensity treatment protocols.